STOCK TITAN

Zomedica Corp. (ZOMDF) grants 500,000 stock options to its COO

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Zomedica Corp. reported that COO Blair Anthony K received a grant of options to buy 500,000 shares of Common Stock on August 5, 2026, with an exercise price of $0.09 per share and an expiration date of August 4, 2036. One quarter of the options vest on the first anniversary of the grant date, with the remaining options vesting in equal monthly installments until fully vested on August 4, 2030, leaving a reported holding of 500,000 options after the grant.

Positive

  • None.

Negative

  • None.
Insider Blair Anthony K
Role COO
Type Security Shares Price Value
Grant/Award Options to buy Common Stock F1 500,000 $0.00 $0.00
Holdings After Transaction: Options to buy Common Stock — 500,000 shares (Direct)
Footnotes (1)
  1. F1. one quarter (1/4) of the options to vest on the first anniversary of the date of grant and 1/48 to vest monthly thereafter until fully vested on 8/4/2030
Options granted 500,000 options Grant of options to buy Common Stock to COO Blair Anthony K
Exercise price $0.09 per share Exercise price for the granted stock options
Option expiration date August 4, 2036 Expiration date of the granted stock options
Full vesting date August 4, 2030 Date on which options are fully vested under the schedule
Grant date August 5, 2026 Transaction date for the option grant
Options to buy Common Stock financial
"Security titled 'Options to buy Common Stock' with underlying Common Stock shares."
exercise price financial
"Conversion or exercise price reported as $0.0900 per share for the options."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"An expiration date of 2036-08-04 is specified for the stock options."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
fully vested financial
"Options become fully vested on 8/4/2030 under the stated vesting schedule."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Zomedica (ZOMDF) report for COO Blair Anthony K?

Zomedica reported that COO Blair Anthony K received a grant of options to buy 500,000 shares of Common Stock at an exercise price of $0.09 per share, expiring on August 4, 2036, as part of his equity-based compensation.

How many options did Zomedica (ZOMDF) grant to its COO and at what price?

The COO of Zomedica received 500,000 stock options with an exercise price of $0.09 per share. These options relate to Common Stock and were reported as directly owned derivative securities following the transaction.

What is the vesting schedule for the Zomedica (ZOMDF) COO’s 500,000 options?

The vesting schedule provides that one quarter (1/4) of the options vest on the first anniversary of the grant, with 1/48 of the options vesting monthly thereafter until all options are fully vested on August 4, 2030, subject to continued service terms.

When do the newly granted Zomedica (ZOMDF) COO options expire?

The options granted to the Zomedica COO have an expiration date of August 4, 2036. After that date, any unexercised options will lapse, and the right to purchase the underlying Common Stock at $0.09 per share will terminate.

How many options does the Zomedica (ZOMDF) COO hold after this grant?

Following this transaction, the Zomedica COO is reported to hold 500,000 options to buy Common Stock directly. These options are subject to the specified vesting schedule and carry an exercise price of $0.09 per share until their 2036 expiration.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Blair Anthony K

(Last)(First)(Middle)
1101 TECHNOLOGY DRIVE
STE 100

(Street)
ANN ARBOR MICHIGAN 48108

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Zomedica Corp. [ ZOMDF ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
COO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Options to buy Common Stock$0.0908/05/2026A500,000 (1)08/04/2036Common Stock500,000$0.00500,000D
Explanation of Responses:
1. one quarter (1/4) of the options to vest on the first anniversary of the date of grant and 1/48 to vest monthly thereafter until fully vested on 8/4/2030
Remarks:
(1) one quarter (1/4) of the options to vest on the first anniversary of the date of grant and 1/48 to vest monthly thereafter until fully vested on 8/4/2030
/s/ Anthony K. Blair08/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)